Tivozanib Completed Phase 2 Trials for Glioblastomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01846871Tivozanib for Recurrent Glioblastoma